Memory Pharmaceuticals Corp. Files Registration Statement for Initial Public Offering of Common Stock
Montvale, New Jersey - December 23, 2003 - Memory Pharmaceuticals Corp. (the "Company") announced today that it has filed a registration statement with the Securities and Exchange Commission relating to an initial public offering of its common stock. All the shares of common stock to be offered by the Company will be newly issued shares.
UBS Securities LLC is acting as the sole book-runner. SG Cowen Securities Corporation is acting as co-lead manager, with Banc of America Securities LLC and Fortis Securities Inc. acting as co-managers. The offering will be made only by means of a prospectus, a copy of which may be obtained, when available, from UBS Securities LLC, ECMG Syndicate Department, 299 Park Avenue, New York, NY 10171.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
About the Company
Memory Pharmaceuticals Corp. is a biopharmaceutical company focused on the development of innovative drug candidates for the treatment of central nervous system, or CNS, conditions that exhibit significant impairment of memory and other cognitive functions. These conditions include neurological diseases associated with aging, such as Alzheimer's disease, vascular dementia and mild cognitive impairment, and also include certain psychiatric disorders such as depression and schizophrenia.